📊 CTMX Key Takeaways
Is CytomX Therapeutics, Inc. (CTMX) a Good Investment?
CytomX is burning $25.5M annually in operating cash while generating only $10.3M in flat-growth revenue, resulting in -177.9% net margins and negative returns on both equity and assets. Although the strong balance sheet ($28.8M cash, minimal debt) provides ~13 months of runway at current burn rates, the company faces imminent pressure to achieve profitability, raise capital (potentially dilutive), or achieve major revenue inflection with no evidence of near-term improvement.
CytomX Therapeutics shows weak fundamental quality: revenue was flat, operating margins remain deeply negative, and free cash flow was severely negative relative to revenue. While the balance sheet is lightly levered and current liquidity ratios look healthy on paper, the cash balance is very small relative to the scale of annual operating cash burn, creating significant financing risk unless operating performance improves materially.
CytomX Therapeutics, Inc. Key Strengths (CTMX)
- Fortress balance sheet with $319.9M equity and only $1.6M debt
- Minimal leverage (0.00x debt/equity) provides financial flexibility
- Excellent liquidity (10.38x current ratio) for near-term obligations
- Low leverage with debt/equity of 0.02x limits balance-sheet strain
- Current and quick ratios of 3.09x indicate acceptable near-term balance-sheet liquidity
- Net loss improved year over year, suggesting some expense discipline or non-operating improvement
CTMX Stock Risks: CytomX Therapeutics, Inc. Investment Risks
- Severe cash burn of $25.5M annually with only ~13 months of runway at current rate
- Zero revenue growth YoY despite operating losses exceeding revenue by 1.9x
- Operating margin of -191.8% indicates core business model not generating returns
- Negative ROE (-5.7%) and ROA (-5.1%) destroying shareholder and asset value
- Pharmaceutical sector maturity required but company shows minimal revenue generation capability
- Likely future capital raise or asset sale needed within 12-18 months
- Operating cash flow of -$75.59M versus only $12.67M in cash implies a very short cash runway
- Revenue growth of 0.0% indicates weak top-line momentum and poor growth quality
- Negative operating margin, net margin, ROE, and ROA show the business remains structurally unprofitable
Key Metrics to Watch
- Quarterly cash burn trend and cash runway forecast
- Revenue growth inflection or major commercial milestone announcements
- Clinical pipeline progress and regulatory approval timelines
- Operating expense reduction initiatives or restructuring plans
- Capital raise announcements and dilution impact
- Quarterly operating cash burn relative to cash and equivalents
- Revenue growth and operating margin improvement
CytomX Therapeutics, Inc. (CTMX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.38x current ratio provides a solid financial cushion.
CTMX Profit Margin, ROE & Profitability Analysis
CTMX vs Healthcare Sector: How CytomX Therapeutics, Inc. Compares
How CytomX Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CytomX Therapeutics, Inc. Stock Overvalued? CTMX Valuation Analysis 2026
Based on fundamental analysis, CytomX Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CytomX Therapeutics, Inc. Balance Sheet: CTMX Debt, Cash & Liquidity
CTMX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CytomX Therapeutics, Inc.'s revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.38 reflects profitable operations.
CTMX Revenue Growth, EPS Growth & YoY Performance
CTMX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.3M | -$18.2M | $-0.10 |
| Q3 2025 | $6.0M | -$154.0K | $0.07 |
| Q2 2025 | $18.7M | -$154.0K | $0.00 |
| Q1 2025 | $41.5M | $13.8M | $0.17 |
| Q3 2024 | $26.4M | -$1.1M | $-0.02 |
| Q2 2024 | $24.7M | -$1.1M | $-0.02 |
| Q1 2024 | $23.5M | -$3.3M | $-0.05 |
| Q3 2023 | $11.1M | -$1.1M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CytomX Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CTMX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CytomX Therapeutics, Inc. (CIK: 0001501989)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTMX
What is the AI rating for CTMX?
CytomX Therapeutics, Inc. (CTMX) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTMX's key strengths?
Claude: Fortress balance sheet with $319.9M equity and only $1.6M debt. Minimal leverage (0.00x debt/equity) provides financial flexibility. ChatGPT: Low leverage with debt/equity of 0.02x limits balance-sheet strain. Current and quick ratios of 3.09x indicate acceptable near-term balance-sheet liquidity.
What are the risks of investing in CTMX?
Claude: Severe cash burn of $25.5M annually with only ~13 months of runway at current rate. Zero revenue growth YoY despite operating losses exceeding revenue by 1.9x. ChatGPT: Operating cash flow of -$75.59M versus only $12.67M in cash implies a very short cash runway. Revenue growth of 0.0% indicates weak top-line momentum and poor growth quality.
What is CTMX's revenue and growth?
CytomX Therapeutics, Inc. reported revenue of $10.3M.
Does CTMX pay dividends?
CytomX Therapeutics, Inc. does not currently pay dividends.
Where can I find CTMX SEC filings?
Official SEC filings for CytomX Therapeutics, Inc. (CIK: 0001501989) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTMX's EPS?
CytomX Therapeutics, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CTMX's fundamental grade?
Based on our AI fundamental analysis in June 2026, CytomX Therapeutics, Inc. has a C grade with 81% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CTMX stock overvalued or undervalued?
Valuation metrics for CTMX: ROE of -5.7% (sector avg: 15%), net margin of -177.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CTMX's AI grade for 2026?
Our dual AI analysis gives CytomX Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTMX's free cash flow?
CytomX Therapeutics, Inc.'s operating cash flow is $-25.5M, with capital expenditures of $0.0. FCF margin is -249.1%.
How does CTMX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -177.9% (avg: 12%), ROE -5.7% (avg: 15%), current ratio 10.38 (avg: 2).